事件：公司发布2025 年中报。 2025 年上半年公司实现营业收入15.99 亿元，同比增长11.99%；实现归母净利润3.74 亿元，同比增长 26.16%（若扣除限制性股票激励计划和员工持股计划涉及的股份支付费用影响后，归母净利润约3.87 亿元，同比增长30.83%）；实现扣非归母净利润3.72 亿元，同比增长27.24%。单季度来看，2025Q2 公 司实现营业收入7.75 亿元，同比增长2.60%；实现归母净利润1.92 亿元，同比增长25.20%；实现扣非归 母净利润1.90 亿元，同比增长28.30%。 2025 年上半年，公司继续围绕乌灵系列品种进行深度研究，已完成乌灵胶囊改良型新药AD 动物药效学 研究；灵香片正在开展Ⅱ期临床试验；完成乌灵系列3 个治疗方向的项目立项，正在开展临床前的毒理 和药学研究；聚卡波非钙片的IBS-D 注册临床研究正在稳健推进，聚卡波非钙颗粒已提交药品注册上市 申请。2025 年7 月，公司与浙江大学共建智赋食药联合研发中心，依托其在计算机科学、生物医药与食 品科学等多学科交叉领域的前沿技术，利用AI 技术研发食药同源垂类大模型与智能体，借助AI 技术赋 能乌灵菌 ...

2025 年 08 月 25 日 佐力药业(300181.SZ) 2025H1 利润端表现强劲，C 端拓展与产 股价表现 资料来源：Wind 资讯 升幅% 1M 3M 12M 相对收益 1.2 9.6 2.4 绝对收益 7.5 21.4 34.6 李奔 分析师 SAC 执业证书编号：S1450523110001 liben@essence.com.cn 冯俊曦 分析师 SAC 执业证书编号：S1450520010002 fengjx@essence.com.cn 胡雨晴 分析师 SAC 执业证书编号：S1450524080002 huyq4@essence.com.cn 相关报告 乌灵胶囊通过集采快速放 量，经营性现金流大幅增长 2024-07-30 乌灵系列市场空间广阔，百 令胶囊上市放量可期 2024-04-19 -20% -10% 0% 10% 20% 30% 40% 2024-08 2024-12 2025-04 2025-08 佐力药业 沪深300 品研发可期 事件：公司发布 2025 年中报。 2025 年上半年公司实现营业收入 15.99 亿元，同比增长 11.99%；实 现归母净利润 3.74 ...

Group 1 - The company held an investor relations event via conference call, attracting over 70 institutions including Dongwu Securities and Ping An Securities [1] - The event featured a presentation by the board secretary on the company's performance for the first half of 2025, followed by a Q&A session addressing core products and business development [1] - The company aims to achieve a 30% net profit growth rate by 2025 through stock incentives, focusing on the promotion of its key product, Wuling Capsules, and expanding market share through collective procurement [1] Group 2 - The Bailing series products, including Bailing tablets and capsules, have participated in the national Chinese medicine procurement alliance, with 28 provinces issuing procurement execution notices, expecting a 38.51% year-on-year sales growth in the first half of 2025 [2] - The company is optimizing its market layout and sales team for rapid growth in the Chinese medicine granule business, while the Chinese medicine decoction pieces have shown stable growth after excluding special factors [2] - The company is implementing a multi-dimensional strategy for the C-end market, including organizational optimization, market expansion, O2O online operations, and consumer education to increase C-end sales proportion [2]

Group 1: Company Performance and Strategy - The company aims for a 30% growth in net profit for 2025, leveraging the dual advantages of its core product, Wuling Capsule, as a national essential medicine and a procurement variety [3] - In the first half of 2025, the sales revenue of the Bailing series increased by 38.51% year-on-year, with expectations for further market share expansion through price-volume strategies [5] - The sales revenue of traditional Chinese medicine granules grew by 56.60% year-on-year in the first half of 2025, indicating robust market performance [6] Group 2: Product Development and Market Expansion - Wuling Capsule's promotion focuses on enhancing hospital coverage and deepening existing relationships, with plans to penetrate community health services and township hospitals [2] - The company has initiated the development of innovative health products targeting insomnia, anxiety, and memory improvement, in collaboration with Zhejiang University [4] - The company has completed the filing of 468 national and provincial standards for traditional Chinese medicine granules, indicating a strong market presence [6] Group 3: C-end Market Strategy - The company is implementing a multi-dimensional strategy to enhance its C-end market presence, including optimizing organizational structure and strengthening market expansion efforts [7] - Plans include promoting online operations and enhancing consumer education regarding the benefits of Wuling Capsule in cognitive function improvement [7] - The company aims to increase C-end sales significantly, with a gradual rise in market share [7] Group 4: Clinical Development and Collaborations - The clinical pipeline of Lingyi Biotech, in which the company has invested, is progressing well, with several projects in various stages of clinical trials [9] - The company is exploring deeper collaborations with Lingyi Biotech in the neurological and psychiatric fields [9] - The focus remains on identifying synergistic opportunities for external development to empower business growth [10]

Investment Rating - The investment rating for the company is "Accumulate" [5] Core Views - The company's revenue for the first half of 2025 reached 1.6 billion yuan, representing a year-on-year growth of 11.99%, while the net profit attributable to shareholders was 374 million yuan, up 26.16% year-on-year [1][2] - The company's gross margin and net margin for Q2 2025 were 65.26% and 25.26%, respectively, showing an upward trend compared to Q2 2024 and Q1 2025, primarily due to an increase in the proportion of high-margin businesses and cost reduction measures [2] - Future growth is anticipated due to the increasing penetration of the company's products and market share gains from collective procurement initiatives [2] Financial Summary - The company adjusted its revenue forecasts for 2025-2027, predicting revenues of 3.221 billion, 3.871 billion, and 4.626 billion yuan, respectively, with corresponding EPS estimates of 0.95, 1.20, and 1.50 yuan [3] - The company reported a significant increase in revenue from its core products, with the Wuling series generating 897 million yuan in H1 2025, a 7.23% increase year-on-year, and the Bailing series achieving 113 million yuan, up 38.5% year-on-year [7] - The traditional Chinese medicine granule business showed rapid growth, with revenues of 74 million yuan in H1 2025, marking a 56.6% year-on-year increase [7] Financial Projections - The projected operating revenues for 2025, 2026, and 2027 are 3.221 billion, 3.871 billion, and 4.626 billion yuan, respectively, with net profits expected to be 676 million, 854 million, and 1.073 billion yuan [9] - The company's gross margin is projected to be 58.9% in 2025, with a net profit margin of 20.6% [9] - The return on equity (ROE) is expected to increase from 18.3% in 2024 to 21.1% in 2025, reaching 30.3% by 2027 [9]

Industry Overview - The pharmaceutical industry is experiencing steady growth, driven by core products and strategic market expansions [3][4]. Company Performance - The company reported a revenue of 1.599 billion yuan for H1 2025, an increase of 11.99% year-on-year, and a net profit of 374 million yuan, up 26.16% year-on-year [4][5]. - The gross margin was 63.01%, reflecting a year-on-year increase of 0.39 percentage points, while the net margin reached 23.71%, up 2.72 percentage points [4]. Core Product Growth - The core products, including the Wuling series and Bailing series, have shown robust growth, with Wuling series sales reaching 897 million yuan (up 7.23%) and Bailing series sales at 113 million yuan (up 38.51%) [5][6]. Strategic Initiatives - The company is implementing a "one body, two wings" strategy, focusing on marketing and R&D to enhance operational performance [6]. - The company is expanding its C-end business by launching larger packaging for Wuling capsules and forming strategic partnerships with major chains [6]. Clinical Validation and R&D Progress - The core product Wuling capsules have received validation from international journals, confirming their safety and efficacy in treating mild depression in Parkinson's patients [7]. - The company has made significant progress in clinical trials, with multiple products entering various stages of development [7]. Profit Forecast - The company is expected to achieve revenues of 3.231 billion yuan, 3.687 billion yuan, and 4.265 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 25.4%, 14.1%, and 15.7% [8]. - Net profits are projected to be 661 million yuan, 839 million yuan, and 986 million yuan for the same years, with growth rates of 30.2%, 26.9%, and 17.4% [8][9].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [5][18]. Core Insights - The company has demonstrated strong profit growth, with a reported revenue of 1.599 billion yuan in H1 2025, reflecting a year-on-year increase of 11.99%. The net profit attributable to shareholders reached 374 million yuan, up 26.16% year-on-year [2][3]. - The core products, including Wuling Capsules and Lingze Tablets, are listed in the national essential drug list, with Wuling Capsules being a unique product. The company is expected to achieve revenue of 29.72 billion yuan in 2025, with a year-on-year growth of 15.3% [9]. Financial Performance Summary - Revenue and Profit Growth: - 2023A: Revenue of 1,942 million yuan, net profit of 383 million yuan - 2024A: Revenue of 2,578 million yuan, net profit of 508 million yuan - 2025E: Revenue of 2,972 million yuan, net profit of 663 million yuan - 2026E: Revenue of 3,459 million yuan, net profit of 800 million yuan - 2027E: Revenue of 4,012 million yuan, net profit of 971 million yuan [1][10]. - Profitability Metrics: - The company’s return on equity (ROE) is projected to increase from 14.1% in 2023 to 25.4% in 2027, indicating improving profitability [1][10]. - The net profit margin for H1 2025 was reported at 23.35%, an increase of 2.62 percentage points year-on-year [3]. Product Performance - In H1 2025, the revenue breakdown by product was as follows: - Wuling series: 897 million yuan (+7.23% YoY) - Bailing Tablets: 113 million yuan (+38.51% YoY) - Traditional Chinese Medicine pieces: 349 million yuan (-10.10% YoY) - Chinese medicine formula granules: 74 million yuan (+56.60% YoY) [3][4]. Marketing and R&D Strategy - The company is enhancing its marketing and R&D efforts, focusing on expanding its channel layout and market coverage. It has partnered with Baidu Health and various pharmacy chains to strengthen its influence in the consumer market [4]. - R&D initiatives include deepening studies on the Wuling series and expanding clinical applications, with Wuling Capsules now included in 83 clinical guidelines and pathways [4].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a revenue of 1.599 billion yuan for the first half of 2025, representing a year-on-year growth of 11.99%. The net profit attributable to shareholders was 374 million yuan, up 26.16% year-on-year, while the net profit after deducting non-recurring gains and losses was 372 million yuan, reflecting a growth of 27.24% year-on-year [2][4]. - In Q2 2025, the company achieved a revenue of 775 million yuan, which is a 2.60% increase year-on-year. The net profit attributable to shareholders for this quarter was 192 million yuan, showing a year-on-year growth of 25.20%, and the net profit after deducting non-recurring gains and losses was 190 million yuan, up 28.30% year-on-year [2][4]. Financial Performance - The company’s core products, including the Wuling series and the Bailing series, have shown significant growth, with increases of 7.23%, 38.51%, and 56.60% respectively in H1 2025, contributing to the overall revenue growth [10]. - The gross profit margin for H1 2025 was 63.01%, an increase of 0.39 percentage points year-on-year, while the net profit margin was 23.35%, up 2.62 percentage points year-on-year [10]. - The company’s sales expenses were 500 million yuan, a year-on-year increase of 2.31%, with a sales expense ratio of 31.23%, down 2.96 percentage points year-on-year. Management expenses decreased by 9.15% year-on-year to 49 million yuan, with a management expense ratio of 3.03% [10]. Future Outlook - The company expects to achieve net profits of 660 million yuan, 845 million yuan, and 1.084 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding earnings per share (EPS) of 0.94 yuan, 1.21 yuan, and 1.55 yuan [10].

Group 1 - The core viewpoint of the article is that Zhaoli Pharmaceutical reported significant growth in both revenue and net profit for the first half of 2025, indicating a positive financial performance [2] Group 2 - The company achieved operating revenue of 1,599,453,446.18 yuan, representing a year-on-year increase of 11.99% [2] - The net profit attributable to shareholders of the listed company was 373,500,159.82 yuan, reflecting a year-on-year growth of 26.16% [2]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 20% compared to the benchmark index within six months [10][14]. Core Insights - The company has demonstrated rapid revenue growth, with a 11.99% increase in revenue to 1.599 billion yuan in H1 2025, and a 26.16% rise in net profit to 374 million yuan [3][4]. - The company's strategic focus on channel expansion and product development is evident, particularly in the "one body, two wings" strategy aimed at enhancing market penetration [6][9]. - The financial outlook is positive, with projected revenues of 3.125 billion yuan, 3.761 billion yuan, and 4.442 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 661 million yuan, 851 million yuan, and 1.050 billion yuan [10][12]. Company Overview - The latest closing price is 20.28 yuan, with a total market capitalization of 14.2 billion yuan [2]. - The company has a total share capital of 701 million shares, with 603 million shares in circulation [2]. - The major shareholder is Yu Youqiang [2]. Financial Performance - In H1 2025, the gross margin was 63.01%, and the net profit margin was 23.35%, indicating strong profitability [4]. - The company reported a significant increase in operating cash flow, which rose by 34.47% to 290 million yuan [3]. - The sales expense ratio decreased by 2.95 percentage points to 31.23%, while the management expense ratio fell by 0.71 percentage points to 3.03% [4]. Business Segments - The pharmaceutical manufacturing segment achieved revenue of 1.254 billion yuan, growing by 10.28%, while the pharmaceutical distribution segment saw a 19.32% increase to 341 million yuan [5]. - Key products such as the Wuling series and traditional Chinese medicine formula granules showed notable growth, with the Wuling series revenue increasing by 7.23% to 897 million yuan and the formula granules by 56.60% to 74 million yuan [5]. Strategic Initiatives - The company is actively enhancing its marketing system and channel layout, focusing on the outpatient market and establishing strategic partnerships with leading chains [6][9]. - A recent investment of 20 million yuan in Lingyi Biotechnology allows the company to secure distribution rights for a Parkinson's treatment in mainland China [9].